filmov
tv
SPS 2018: Implementing Human iPSC-derived Cells in Early Safety Assessment & Disease Modeling
Показать описание
This talk was presented at the 2018 Safety Pharmacology Society Annual Meeting in Washington DC, October 2, 2018.
Dr. T.K. Feaster discusses the predictive power of human iPSC-derived cells for in vitro toxicity testing. He highlighted toxicology, drug screening, and disease models; demonstrating increased functionality and throughput valuable for identifying liabilities early in preclinical safety programs.
Dr. Sonja Stoelzle-Feix discusses the effects of “CiPA drugs” on excitation-contraction coupling in iCell Cardiomyocytes2. She describes the evaluation of the proarrhythmic potential of 23 blinded drugs on hiPSC-CMs using iCell Cardiomyocytes2 and the Nanion CardioExcyte 96 at different sites. Ion channel data and myocyte behavior are discussed and aligned.
Dr. T.K. Feaster discusses the predictive power of human iPSC-derived cells for in vitro toxicity testing. He highlighted toxicology, drug screening, and disease models; demonstrating increased functionality and throughput valuable for identifying liabilities early in preclinical safety programs.
Dr. Sonja Stoelzle-Feix discusses the effects of “CiPA drugs” on excitation-contraction coupling in iCell Cardiomyocytes2. She describes the evaluation of the proarrhythmic potential of 23 blinded drugs on hiPSC-CMs using iCell Cardiomyocytes2 and the Nanion CardioExcyte 96 at different sites. Ion channel data and myocyte behavior are discussed and aligned.
0:55:27
0:14:16
0:23:10
1:13:24
0:59:32
1:08:07
1:14:03
0:49:19
0:12:32
0:22:55
0:26:08
0:46:11
0:29:04
1:23:24
0:33:26
0:03:11
0:55:22
0:05:50
1:16:40
0:29:24
0:40:18
0:33:59
0:16:26